周一，Oppenheimer调整了对Marinus Pharmaceuticals (NASDAQ:MRNS)的立场，将该股评级从"持平"上调至"跑赢大市"。该公司还为Marinus设定了6.00美元的目标价。 此次上调评级之际，Marinus Pharmaceuticals最近举办了一场重要意见领袖(KOL)活动，重点讨论了其口服药物候选ganaxolone (GNX)在治疗结节性硬化症(TSC ...

RADNOR, Pa. - 专注于开发癫痫疾病治疗方案的Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)即将发布其药物ZTALMY®(ganaxolone)用于治疗结节性硬化症(TSC)患者的关键第三期试验数据。TSC是一种可导致严重神经系统问题和难治性癫痫的遗传疾病。TrustTSC试验的顶线数据预计将在2024年第四季度上半年公布,计划于2025年4月提交 ...

is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

Currently, ganaxolone is the sole marketed as well as the only pipeline drug in Marinus’ portfolio. The pipeline setback in ...

In addition, we are excited to share that we expect the patent office to grant new intellectual property for ganaxolone that covers the titration regimen used in the TrustTSC trial. With a U.S ...

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today is hosting an Investor and Analyst Day ...

RADNOR, PA — Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) is set to host its Investor & Analyst Day on September 20 in New ...

Leerink Partners analyst Marc Goodman maintained a Buy rating on Marinus (MRNS – Research Report) on September 11 and set a price target ...

Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded ...

Six rare disease organizations have co-funded a $275,000 grant to Orrin Devinsky, MD, of NYU Grossman School of Medicine, to ...

has approved ganaxolone oral suspension for the treatment of epileptic seizures in patients two years of age and older with CDKL5 deficiency disorder (CDD). PTC Therapeutics (PTCT) witnessed a ...